Opinion statement
Although parathyroid neoplasms are common and cause primary hyperparathyroidism, parathyroid carcinoma is a rare entity. At times it can be difficult to diagnose. Patients with parathyroid carcinoma usually present with profound symptoms of hyperparathyroidism and highly elevated serum calcium and parathyroid hormone (PTH) levels. At the time of neck exploration, a large, gray-white, locally invasive tumor is commonly encountered. The course of patients with parathyroid carcinoma is variable; unfortunately, more than 50% have persistent or recurrent disease due to regional or distant disease. Surgical resection is the principal treatment for patients with parathyroid carcinoma. The optimal surgical treatment is en bloc tumor resection with ipsilateral thyroid lobectomy when the diagnosis is suspected and until it is proven otherwise. Patients who have persistent or recurrent parathyroid carcinoma should have localizing studies to identify loco-regional or distant tumor sites. Reoperation in patients with localized parathyroid carcinoma is recommended because it relieves symptoms of hypercalcemia, and it normalizes serum calcium and PTH levels in most patients. For patients who have unresectable parathyroid carcinoma, a protocol-based treatment with chemotherapy and external radiotherapy should be considered. Additionally, second-generation bisphosphonates and the NPS R-568 calcimimetic agent may be useful in normalizing the serum calcium and improving symptoms of hypercalcemia. However, they do not treat the tumor and are rarely effective in the long term.
Similar content being viewed by others
References and Recommended Reading
McKeown PP, McGarity WC, Sewell CW: Carcinoma of the parathyroid gland: is it overdiagnosed? A report of three cases. Am J Surg 1984, 147:292–298.
Levin KE, Galante M, Clark OH: Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 1987, 101:649–660.
Obara T, Fujimoto Y: Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg 1991, 15:738–744.
Favia G, Lumachi F, Polistina F, D’Amico DF: Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg 1998, 22:1225–1230.
Kebebew E, Clark OH: Parathyroid adenoma, hyperplasia, and carcinoma. Localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Surg Oncol Clin North Am 1998, 7:721–748.
Kebebew E, Arici C, Duh Q-Y, Clark OH: Reoperation for persistent and recurrent parathyroid carcinoma. Arch Surg 2001, In press. A single-institution, comprehensive study evaluating the long-term outcome of patients who had reoperation for persistent and recurrent parathyroid carcinoma.
Cryns VL, Thor A, Xu HJ, et al.: Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994, 330:757–761.
Hakim JP, Levine MA: Absence of p53 point mutations in parathyroid adenoma and carcinoma. J Clin Endocrinol Metab 1994, 78:103–106.
Schantz A, Castleman B: Parathyroid carcinoma: a study of 70 cases. Cancer 1973, 31:600–605.
Levin KE, Chew KL, Ljung BM, et al.: Deoxyribonucleic acid cytometry helps identify parathyroid carcinoma. J Clin Endocrinol Metab 1988, 67:779–784.
Sandelin K, Auer G, Bondeson L, et al.: Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 1992, 16:724–731.
Hundahl|SA, Fleming ID, Fremgen AM, Menck HR: Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995. A National Cancer Data Base report. Cancer 1999, 86:538–544. A large, retrospective cancer registry-based study of parathyroid cases with an analysis of prognostic factors. It also highlights the limitation of staging for parathyroid carcinoma and that the majority of patients receive incomplete initial surgical resection.
Fujimoto Y, Obara T, Ito Y, et al.: Localization and surgical resection of metastatic parathyroid carcinoma. World J Surg 1986, 10:539–547.
Calandra DB, Cheijfec G, Foy BK, et al.: Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 1984, 96:1132–1137.
Shane E: Parathyroid carcinoma. Curr Ther Endocrinol Metab 1994, 5:522–525.
Chow E, Tsang RW, Brierley JD, Filice S: Parathyroid carcinoma —the Princess Margaret Hospital experience. Int J Radiat Oncol 1998, 3:569–572.
Wynne AG, van Heerden J, Carney JA, Fitzpatrick LS.: Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine 1992, 71:197–205.
Collins MT, Skarulis MC, Bilezikian JP, et al.: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998, 83:1083–1088. A case report of a patient with hypercalcemia due to unresectable parathyroid carcinoma who was treated effectively with a calcimimetic agent.
Schott M, Feldkamp J, Schattenberg D, et al.: Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 2000, 142:300–306.
Schott M, Seissler J, Feldkamp J, et al.: Dendritic cell immunotherapy induces antitumor response in parathyroid carcinoma and neuroendocrine pancreas carcinoma. Horm Metab Res 1999, 31:662–664.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kebebew, E. Parathyroid carcinoma. Curr. Treat. Options in Oncol. 2, 347–354 (2001). https://doi.org/10.1007/s11864-001-0028-2
Issue Date:
DOI: https://doi.org/10.1007/s11864-001-0028-2